Amgen - Targeting KRASG12C: A new era for patients with advanced NSCLC

Time
12:45 - 14:15

Welcome and introduction

Targeting KRASG12C: A new era in second-line treatment of patients with NSCLC

The turning point: Practical considerations when emerging biomarkers become actionable

Forward thinking: Future perspectives in targeting KRAS in NSCLC

Panel discussion and Q&A

Summary and close